Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) deny the claims. Marston’s new role comes at a time when one in eight U.S. adults are using GLP-1 class medications, making the case ...

Meanwhile, in case Novo Nordisk can’t convince regulators of oral semaglutide’s merits first time around, it has a large-scale cardiovascular outcome study called SOUL in preparation that ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Novo Nordisk states that 442 cases of adverse events associated with these products have been reported to the FDA, 319 of which were classified as serious. There have also been issues of fake ...

Novo Nordisk, which did not fund the new Case Western study, is also examining semaglutide in a late-stage study on Alzheimer's patients. The new Case Western study released Thursday builds on ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Novo Nordisk is still growing at a high pace and is expanding into new therapeutic areas like Alzheimer's disease, cardiovascular disease, or MASH. But the competition from Eli Lilly increases as ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's (NVO ... The research was conducted by researchers at Case Western Reserve University School of Medicine without the ...